|1.||Sundar, Shyam: 23 articles (01/2015 - 11/2002)|
|2.||Dorlo, Thomas P C: 12 articles (12/2015 - 08/2008)|
|3.||Gupta, Suman: 10 articles (10/2015 - 04/2005)|
|4.||Das, Pradeep: 9 articles (02/2016 - 03/2009)|
|5.||Sindermann, Herbert: 9 articles (08/2007 - 11/2002)|
|6.||Pandey, Krishna: 8 articles (02/2016 - 08/2007)|
|7.||Beijnen, Jos H: 8 articles (07/2014 - 08/2008)|
|8.||Ramesh, V: 7 articles (10/2015 - 01/2008)|
|9.||Rivas, Luis: 7 articles (06/2015 - 10/2006)|
|10.||Dujardin, Jean-Claude: 7 articles (07/2014 - 08/2012)|
|1.||Visceral Leishmaniasis (Kala Azar)
05/01/2007 - "Oral miltefosine, which is very effective in visceral leishmaniasis caused by L. "
01/01/2013 - "Miltefosine is currently the latest and only oral antileishmanial that came out of drug discovery pipelines in the past few decades, but recent reports indicate a significant decline in its efficacy against visceral leishmaniasis (also known as kala-azar) in the Indian subcontinent. "
12/01/2006 - "Miltefosine, an alkyl phospholipid has been found effective against visceral leishmaniasis (VL) in adults in various studies. "
01/01/2015 - "Miltefosine has been found to be effective in the treatment of Visceral Leishmaniasis (VL). "
07/01/2012 - "Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis."
08/28/2014 - "Therefore, the identification of miltefosine, an effective and safe oral drug, was considered a significant advancement in leishmaniasis therapy. "
04/01/2006 - "Miltefosine is the first effective and safe oral agent with the potential to treat all major clinical presentations of leishmaniasis."
11/01/2012 - "Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis."
12/09/2006 - "[Miltefosine: a new remedy for leishmaniasis]."
01/01/2014 - "We report here the preliminary results of a phase II clinical trial in patients with mucosal leishmaniasis, in which the efficacy of oral miltefosine versus the antimonial compound was assessed. "
11/01/2001 - "The clinical results suggest that miltefosine is the first oral therapy that is effective and safe in visceral and cutaneous leishmaniasis."
08/01/2010 - "Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis."
02/01/2008 - "Efficacy of miltefosine for Bolivian cutaneous leishmaniasis."
04/01/2012 - "The use of miltefosine in cutaneous leishmaniasis has been addressed in a few clinical trials. "
04/01/2012 - "Miltefosine is being tested with small clinical trials mainly in endemic cutaneous leishmaniasis regions of South America and Iran. "
10/01/2011 - "These findings revealed that this lipopeptide has potential protective efficacy which significantly enhanced the therapeutic efficacy of miltefosine used at low dose against Leishmania infection and warrants detailed investigations on its possible immunopotentiatory actions."
12/01/2008 - "Cutaneous infection with Leishmania infantum in an infant treated successfully with miltefosine."
09/01/2011 - "Miltefosine has antifungal properties and potential for development as a therapeutic for invasive fungal infections. "
03/01/1998 - "These results demonstrate the short-term efficacy of HDPC against an established Leishmania infection. "
03/01/1998 - "Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice."
11/01/2010 - "Treatment of the experimentally infected animals with a topical paromomycin-oral miltefosine combination induced a statistically significant reduction in lesion size and parasite burden in the skin and spleen, with complete healing of ulcers, compared with those treated with a placebo group. "
12/01/2009 - "Treatment of the experimentally infected animals with topical paromomycin + oral miltefosine combination induced a statistically significant reduction in lesion size and parasite burden in the skin, with complete healing of ulcers, as compared with those treated with oral miltefosine or placebo. "
07/01/2009 - "After treatment with miltefosine, the ulcer resolved completely, and infliximab was reinstituted because of progression of spondylitis. "
|2.||Paromomycin (Paromomycin Sulfate)
|3.||Amphotericin B (Amphotericin)
|5.||liposomal amphotericin B
|7.||Antineoplastic Agents (Antineoplastics)
|8.||Antimony Sodium Gluconate (Sodium, Stibogluconate)
|1.||Drug Therapy (Chemotherapy)